Pharma marketing doesn't fail on strategy – it fails on the operational layer underneath it: review workflows that stall everything, HCP and patient data systems that weren't built for compliance, and agency handoffs that lose a week every time. We fix the machinery so campaigns actually ship.
The Problem
MLR review is a bottleneck because nobody designed the workflow, it just accumulated
Most medical-legal-regulatory review processes grew ad hoc – a shared drive, an email chain, a spreadsheet tracker someone built three brand managers ago. Assets bounce between legal, medical, and regulatory reviewers with no clear routing logic, no version control, and no visibility into where something is stuck. A campaign that should take two weeks to clear review takes six, and the launch calendar bends around the bottleneck instead of the other way around.
CRM and MAP systems built for consumer marketing weren't built for HCP and patient data compliance
Standard marketing automation platforms assume you can email anyone who fills out a form. Pharma marketing operates under opt-in rules for HCP communication, sunshine act reporting on anything of value exchanged with physicians, and patient privacy constraints that make consumer-style nurture sequences a compliance risk. Teams that bolt compliance logic onto a generic MAP after the fact end up with manual workarounds that break every time someone updates a workflow.
Multi-brand, multi-therapeutic-area campaign ops multiply the coordination overhead
A company running three brands across two therapeutic areas doesn't have one marketing ops problem, it has three, each with its own MLR reviewers, its own agency roster, and its own campaign calendar – and they all compete for the same internal review bandwidth. Without a shared operational backbone, each brand team reinvents its own process, and the company loses the efficiency it should get from scale.
Agency and vendor coordination eats weeks that never show up in any budget line
A typical pharma campaign touches a creative agency, a medical education vendor, a congress or speaker program vendor, and internal MLR – and every handoff between them is a place work stalls waiting on someone else's queue. Nobody owns the coordination between vendors, so campaign timelines slip by weeks that get blamed on 'review' when the real cause is nobody managing the handoffs.
How We Help
Our initial assessment maps your actual MLR workflow end to end – not the process on paper, the process assets actually go through. We track a handful of real campaigns from brief to approval, timestamp every handoff, and find where things sit waiting versus where they're genuinely being reviewed. Most companies discover the bottleneck isn't reviewer capacity, it's routing logic and unclear ownership of who reviews what and in what order.
Strategy development redesigns the review workflow around parallel review where compliant, clear escalation paths for disputed claims, and a routing system tied to asset type and risk level rather than one queue for everything. We also assess your CRM and MAP configuration against actual HCP and patient data compliance requirements – opt-in tracking, sunshine act reportable interactions, consent management – and identify where the current setup creates manual risk instead of automated compliance.
Execution implements the rebuilt workflow inside the systems you already use wherever possible, since replacing a CRM or MAP platform is rarely worth the disruption. We build the review routing, set up compliant data handling for HCP and patient records, and create the campaign operations calendar that coordinates across brands and therapeutic areas instead of letting each team run its own silo. For multi-brand companies, we build a shared operational backbone with brand-specific flexibility layered on top, so each brand isn't rebuilding the same process from scratch.
Measurement tracks the operational metrics that actually predict whether marketing ships on time: average MLR cycle time by asset type, percentage of campaigns launched on original schedule, and agency/vendor handoff time. This isn't a strategy scorecard – it's the operational data that tells you whether the machinery underneath the strategy is actually working.
What we deliver
- MLR workflow redesign – routing logic, parallel review paths, and escalation process mapped to asset type and risk
- Compliant CRM/MAP configuration for HCP and patient data, including opt-in and sunshine act tracking
- Multi-brand campaign operations calendar and shared operational backbone across therapeutic areas
- Agency and vendor coordination process with clear ownership at every handoff point
Pharma marketing teams rarely lose to a bad strategy. They lose to a six-week MLR queue with no routing logic, built one ad hoc fix at a time until nobody remembers why it works the way it does.
Our Methodology
Our 90-day marketing operations build starts by tracing real campaigns through your actual workflow, not the documented one. Phase one instruments a handful of live or recent campaigns end to end and timestamps every step to find where time is actually lost, while auditing CRM/MAP configuration against HCP and patient data compliance requirements to find manual workarounds masking as process.
Phase two redesigns the workflow – routing logic that gets straightforward assets through faster while giving complex claims real scrutiny, clear escalation paths, and the CRM/MAP changes needed for compliant, less manual data handling. Every change goes through your compliance and IT stakeholders before implementation, since marketing ops in pharma can't outrun governance.
Phase three implements the new workflow, reconfigures systems, and trains the brand teams, agencies, and reviewers who operate inside it daily. Unlike a generic marketing ops consultancy that hands over a process diagram, we stay through the first full campaign cycle to fix what breaks in practice, not just in theory.
How We Work
Initial engagements run 3-4 months, long enough to redesign and prove out the workflow through at least one campaign cycle. The first 30 days are the workflow audit – tracing live campaigns, timestamping review stages, and auditing CRM/MAP compliance configuration.
Days 31-60 redesign the MLR routing, campaign calendar, and system configuration, with legal, medical, regulatory, and IT stakeholders reviewing every change before it ships – governance sign-off is not optional and we build the timeline around it.
Days 61-90 implement the new workflow and systems, train the teams and reviewers who use them, and run the first campaign cycle under the new process. From your side we need MLR reviewer access, CRM/MAP admin access, and a named compliance contact.
Weekly sessions track implementation. Monthly reviews with commercial and compliance leadership walk through cycle time, on-schedule launch rate, and vendor handoff time.
- Reduced MLR review cycle time
- Higher percentage of campaigns launching on original schedule
- Compliant CRM/MAP configuration with less manual workaround risk
- Cleaner multi-brand campaign coordination with less duplicated process
If your biotech & pharma company needs marketing operations leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does a marketing operations engagement cost for a biotech or pharma company?
Engagements typically range from $50K-$120K depending on the number of brands and therapeutic areas in scope and whether CRM/MAP reconfiguration is included. A single-brand MLR workflow redesign sits at the lower end; a multi-brand operational backbone with system reconfiguration sits higher. This is well below the cost of the launch delays and review chaos it replaces.
How long before we see faster MLR review times?
Workflow redesign is typically implemented by day 60, with the first campaigns running through the new routing shortly after. Most teams see measurable cycle time improvement within the first campaign or two under the new process, though the full effect – especially for multi-brand coordination – compounds over a full quarter as teams adjust to the new routing logic.
Will you replace our CRM or marketing automation platform?
Usually not. Most compliance gaps are configuration problems, not platform problems, and replacing a CRM or MAP is disruptive enough that it's rarely worth it unless the platform genuinely can't support opt-in tracking or sunshine act reporting. We reconfigure what you have first and only recommend a platform change when the current system is structurally incapable of compliant operation.
How does the marketing operations team work with our compliance and regulatory staff?
Every workflow and system change goes through your legal, medical, and regulatory stakeholders before implementation – we don't design around compliance, we design with it in the room. We typically set a standing review checkpoint with compliance during the strategy phase so nothing gets built that has to be unwound later for a governance objection.
What makes Winston Francois different from a general marketing operations agency?
Most marketing ops agencies have never built a workflow that has to survive an MLR review or a sunshine act audit. We build routing and system configuration around the reality that pharma marketing has mandatory compliance gates a consumer marketing ops build never has to plan for, and we treat those gates as fixed constraints, not obstacles to design around.
What type of biotech or pharma company benefits most from this service?
Companies running more than one brand or therapeutic area, or any company where MLR review time is visibly slowing down launches, get the most value. A single-brand pre-commercial company can also benefit from setting up compliant operational infrastructure before the campaign volume increases post-launch. The first step is tracing a few recent campaigns to see where time is actually being lost.
